Trial Profile
Efficacy and safety of oglemilast in the prevention of allergen-induced bronchospasm.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2012
Price :
$35
*
At a glance
- Drugs Oglemilast (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Forest Laboratories
- 19 May 2006 New trial record.